The third-generation Medtronic CoreValve ReValving System (Medtronic, Minneapolis, Minnesota, United States) was implanted by the same operator in all patients by transfemoral approach with double Pro-Glide (Abbott Vascular, Redwood City, California, United States) preclosing, as previously published.
10 (link)
Procedures were performed under anticoagulation by a bolus of unfractionated heparin at weight-adjusted dose.
The clinical endpoints after TAVI were described following Valve Academic Research Consortium-2 definitions.
11 (link)
In-hospital clinical, biological, and transthoracic echocardiography (TTE) follow-up was performed before discharge. Active 30-day follow-up was obtained in all survivors by outpatient visit or direct contact with their cardiologist. All events and values were prospectively site recorded.